Shwachman-Diamond syndrome (SDS) is a rare inherited recessive disease mainly caused by mutations in the Shwachman-Bodian-Diamond syndrome (SBDS) gene, which encodes for the homonymous protein SBDS, whose function still remains to be fully established. SDS affects several organs causing bone marrow failure, exocrine pancreatic insufficiency, skeletal malformations, and cognitive disorders. About 15% of SDS patients develop myelodysplastic syndrome (MDS) and are at higher risk of developing acute myeloid leukemia (AML). Deficiency in SBDS expression has been associated with increased apoptosis and lack of myeloid differentiation in bone marrow hematopoietic progenitors. Importantly, most SDS patients carry nonsense mutations in SBDS.
and mediate 60S ribosomal subunit binding through regulation of the release of the eukaryotic initiation factor 6 (eIF6). 6 Interestingly, SBDS has also been reported to co-localize with the mitotic spindle, where it appears to directly associate with microtubules and play a role in cell division. 7, 8 Consistently, SDS hematopoietic progenitors are characterized by defective proliferation and increased rate of apoptosis due to excessive accumulation of Fas antigen in the plasma membrane. 9, 10 BM from SDS patients is characterized by decreased frequency of CD34 1 cells, 11, 12 which hampers its ability to form hematopoietic colonies in vitro. 11, 13 In this regard, loss of SBDS gene expression leads to impaired myeloid differentiation also in murine hematopoietic stem cells. 14 Furthermore, deficiency in SBDS gene expression correlates with enhanced phosphorylation of the mammalian target of rapamycin (mTOR), 15, 16 which regulates a number of key hematopoietic stem cell functions. 17 In this regard, SDS cells, despite being characterized by a severely impaired oxidative phosphorylation metabolism, exhibit constitutive hyperphosphorylation of mTOR. 16 Consistently, we have shown that enhanced mTOR S2448 phosphorylation in SDS leukocytes is inhibited by low doses of rapamycin, thus suggesting a role of the rapamycin-sensitive mTOR complex 1 (mTORC1) in SDS pathogenesis. 5 Of note, constitutive activation of mTORC1 signaling has been associated with hematopoietic stem cell impoverishment and leukemogenesis. 18, 19 Interestingly, almost 50% of SDS patients carry the c. Noteworthy, SBDS knock-out results in early embryonic lethality in mice, 20 which is consistent with us and others not having been able so far to identify homozygotes for the c.[183-184TA > TC] mutation. 1 PTCs can be functionally overridden by endogenous alterations in the translation process through a phenomenon known as nonsense suppression, which allows the misreading of PTCs by near-cognate tRNA. 21 Pharmacological nonsense suppression can be achieved by using small molecules, such as aminoglycosides, 22 which promote PTC read-through. 23 Ataluren (PTC124; 3-[5-(2-fluorophenyl)- [1, 2, 4] oxadiazol-3-yl]-benzoic acid) is an orally bio-available compound approved by the European Medicines Agency (EMA) for the treatment of Duchenne muscular dystrophy (DMD). 24 As for aminoglycosides, ataluren promotes the insertion of near-cognate tRNAs at the nonsense codon site resulting in amino acid replacements similar to those observed in endogenous read-through. 25 In this work, we sought to determine whether ataluren treatment of SDS patient-derived hematological and nonhematological cells could restore SBDS protein expression, thereby improving myeloid differentiation of bone marrow progenitors and reducing the apoptotic rate of SDS cells.
| M E TH ODS

| Ethics statement
All human samples used in this work were analyzed only after written informed consent, in accordance with the Declaration of Helsinki. 
| Patients
Lymphoblastoid cell lines (LCLs), mononuclear cells (MNCs), and mesenchymal stromal cells (MSCs) were all obtained from fresh peripheral blood or bone marrow samples derived from diagnostic specimens collected from 13 SDS patients. All patients included in this study were diagnosed as having SDS based on clinical criteria and carried the c.
[183-184TA > CT] nonsense mutation, screened at time of diagnosis.
Importantly, none of the patients was undergoing steroids or granulocyte colony-stimulating factor (G-CSF) (i.e., filgrastim) therapy. Supporting Information Table S1 shows the clinical and genetic characteristics of all SDS patients enrolled in this study.
| Cell cultures
LCLs were obtained from patients carrying the c.[183-184TA > CT] nonsense mutation as previously described. 15 
| Colony assays
MNCs were cultured in 6-well plates at a density of 10 
| Flow cytometry
LCLs were seeded at 2. Navios flow cytometer (Beckman Coulter, Indianapolis, Indiana). All acquired data files were analyzed using the "Navios" or Kaluza software, version 1.3 (Beckman Coulter, Indianapolis, Indiana).
| Elisa
Analysis of phospho-mTOR was also performed by using the PathScan 
| Apoptosis assays
To evaluate the apoptotic rate in SDS cells, we used the eBioscience Finally, 5 lL of propidium iodide were added to cells. Fluorescence signals were acquired using Navios flow cytometer (Beckman Coulter), and data files were analyzed using the Kaluza software, version LCLs and primary PBMCs, we tried to reduce the concentrations. As shown in Figure 1E ,F, treatment of BM-MSCs with 2.5 lM or 5 lM ataluren was able to restore SBDS protein expression also in these cells, albeit with a delayed kinetics (72-96 hours) compared to LCLs (24 hours). Thus, ataluren treatment readily corrects the deficiency in SBDS protein expression in a cell type-independent fashion.
| Ataluren induces ex vivo myeloid differentiation in bone marrow progenitor cells
SDS patients present with generalized bone marrow dysfunction. In particular, hematopoietic progenitors display faulty proliferative properties and increased apoptosis, 9 resulting in diminished number of myeloid lineage cells 12 and reduced ability to form hematopoietic colonies in vitro. 11, 13 To assess the functional role of SBDS expression restoration, we isolated MNCs from 13 BM biopsies obtained from patients carrying nonsense mutations, which due to the rarity of the pathology were obtained using cells derived from three additional patients ( Figure   2D and data not shown).
| Ataluren restores normal level of mTOR S2448 phosphorylation in SDS cells
Recently, we and others have shown constitutive hyper-activation of mTOR signaling in SDS cells. 15, 16 Importantly, aberrant mTOR signaling has been associated with several forms of leukemia and lymphoma, including AML. 29 Furthermore, we have previously shown that silencing of SBDS leads to mTOR hyperphosphorylation at S2448. 
| Ataluren reduces the apoptotic rate of freshly isolated PBMCs obtained from SDS patients
Lack of SBDS expression has been associated with increased apoptosis due to an excessive accumulation of Fas antigen in the plasma membrane and subsequent hyperactivation of the Fas signaling pathway. 9, 10 Interestingly, also resting BM-MNCs obtained from SDS patients show increased apoptosis compared to healthy control cells. 9 Since, we could not use LCLs to study apoptosis because the presence of the viral Table S1 ) or from 13 healthy donors: 5 females, mean age (years) 11.40 6 7.40 (SD); 8 males, mean age 16.00 6 11.20 (SD). Cells were cultured for 28 days in methylcellulose medium in the absence (DMSO) or presence of 2.5 or 5 lM ataluren . A, Comparison of myeloid differentiation between BM-MNCs obtained from healthy donors (white bar) or SDS patients (black bar) after 28 days of incubation. Data are expressed as mean 6 SEM. B, Maximum increase of myeloid CFUs within 28 days of incubation is expressed as the percentage of colonies relative to DMSO control. Data are expressed as mean 6 SEM. P-values were calculated by Student's t test. C, BM-MNCs were isolated from freshly collected biopsies obtained from UPN27. Cells were cultured for 28 days in methylcellulose medium in the presence or in the absence (DMSO alone) of 2.5-5 lM ataluren as described in the Methods section. Total proteins were then extracted from the colonies and subject to WB analysis as described in the legend to Figure 1 . D, Densitometry analysis of WBs was performed as described in the Methods section. Data are expressed as mean 6 SEM of 4 independent experiments performed in BM-MNCs, as reported in panel C. P-values were calculated by Student's t test. *P < .05, **P < .01, ***P < .001 latent protein EBNA3A induces apoptosis resistance during EBVinduced B cell immortalization, 30 we sought to determine the apoptotic rate of primary PBMCs derived from 4 different patients. In good agreement with previous data on BM-MNCs, 9 we found a considerably 
| Ataluren does not affect cell proliferation in SDS lymphoblasts
We have recently reported that rapamycin-mediated inhibition of mTOR S2448 phosphorylation leads to a slight increase in cell proliferation of LCLs. 5 Since also ataluren can reduce mTOR hyperactivation in lymphoblasts and MSCs (Figure 3) , we sought to determine the effect of ataluren on the proliferation of lymphoblastoid cells. For this purpose, we incubated LCLs obtained from two patients with increasing doses (0-20 lM) of ataluren and performed MTT assays at the 24-and 48-hour time point. We found that, unlike rapamycin, ataluren failed to promote cell proliferation of LCLs (Supporting Information Figure S1A ,B). patients (23%) we did not observe an increase in the number of myeloid colonies after 28 days of ataluren treatment. A possible explanation for this observation is that ataluren might in some cases lack of efficacy due to the randomness of its stop codon read-through activity. 25 In any case, our findings are consistent with clinical studies in DMD patients, where ataluren was found to improve dystrophin expression only in 61% of cases. 32 Recently, our group and others have shown hyperactivation of the mTOR pathway in SDS patients. 15, 16 Notably, constitutive hyperactivation of mTOR signaling causes hematopoietic stem cell impoverishment in the BM and leukemogenesis. 18, 19, 29 Furthermore, SBDS-expressing SDS cell lines display a substantial reduction in mTOR phosphorylation levels. 16 Here, we report that the correction of SBDS protein synthesis correlates with a reduction in mTOR phosphorylation levels, which might be indicative of a lower propensity for leukemic transformation.
Taken all together, our preclinical findings provide the rationale for repurposing ataluren as a potential therapeutic agent for the correction of SDS bone marrow dysfunction, a possibility that warrants further investigation in clinical studies. Moreover, this study opens new therapeutic perspectives also for other genetic bone marrow failure syndromes caused by nonsense mutations.
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